Michele Cavo, MD, professor, Seràgnoli Institute of Hematology Bologna University School of Medicine, discusses the results of the phase III EMN02/HO95 MM trial, which compared the efficacy of upfront autologous stem cell transplantation (ASCT) versus novel agent-based therapy for the treatment of patients with multiple myeloma. 

In the study, patients were randomized to receive 4 cycles of bortezomib, melphalan, and prednisone versus high-dose melphalan and single or double ASCT as intensification therapy following induction with bortezomib, cyclophosphamide, and dexamethasone and subsequent collection of peripheral blood stem cells.  

The difference between the 2 arms was statistically significant, Cavo explains. Additionally, there was an improvement in progression-free survival with ASCT. Results show that ASCT remains to be a preferred treatment regimen in newly diagnosed patients with multiple myeloma, he adds.

View more from the 2016 ASCO Annual Meeting

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Multiple Myeloma

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

ASCO Annual Meeting

Michele Cavo, MD, professor, Seràgnoli Institute of Hematology Bologna University School of Medicine, discusses the results of the phase III EMN02/HO95 MM trial, which compared the efficacy of upfront autologous stem cell transplantation versus novel agent-based therapy for the treatment of patients with multiple myeloma.

Dr. Cavo on Upfront ASCT in Multiple Myeloma